BACKGROUND:Maternal highly-active antiretroviral therapy (HAART) reduces mother-to-child HIV transmission but may increase the risk for infant anemia. METHODS: The incidence of first severe anemia (grade 3 or 4, Division of AIDS 2004 Toxicity Table) was assessed among HIV-uninfected infants in the Mashi and Mma Bana mother-to-child HIV transmission prevention trials in Botswana. Severe anemia rates were compared between 3 groups: infants exposed to maternal HAART in utero and during breastfeeding (BF) and 1 month of postnatal zidovudine (ZDV) (HAART-BF); infants exposed to maternal ZDV in utero, 6 months of postnatal ZDV, and BF (ZDV-BF); and infants exposed to maternal ZDV in utero, 1 month of postnatal ZDV, and formula-feeding (ZDV-FF). RESULTS: A total of 1719 infants were analyzed-691 HAART-BF, 503 ZDV-BF, and 525 ZDV-FF. Severe anemia was detected in 118 infants (7.4%). By 6 months, 12.5% of HAART-BF infants experienced severe anemia, compared with 5.3% of ZDV-BF (P < 0.001) and 2.5% of ZDV-FF infants (P < 0.001). In adjusted analysis, HAART-BF infants were at greater risk of severe anemia than ZDV-BF or ZDV-FF infants (adjusted odds ratios 2.6 and 5.8, respectively; P < 0.001). Most anemias were asymptomatic and improved with iron/multivitamin supplementation and cessation of ZDV exposure. However, 11 infants (0.6% of all infants) required transfusion for symptomatic anemia. Microcytosis and hypochromia were common among infants with severe anemia. CONCLUSIONS: Exposure to maternal HAART starting in utero was associated with severe infant anemia. Confirmation of this finding and possible strategies to mitigate hematologic toxicity warrant further study.
RCT Entities:
BACKGROUND: Maternal highly-active antiretroviral therapy (HAART) reduces mother-to-child HIV transmission but may increase the risk for infantanemia. METHODS: The incidence of first severe anemia (grade 3 or 4, Division of AIDS 2004 Toxicity Table) was assessed among HIV-uninfectedinfants in the Mashi and Mma Bana mother-to-child HIV transmission prevention trials in Botswana. Severe anemia rates were compared between 3 groups: infants exposed to maternal HAART in utero and during breastfeeding (BF) and 1 month of postnatal zidovudine (ZDV) (HAART-BF); infants exposed to maternal ZDV in utero, 6 months of postnatal ZDV, and BF (ZDV-BF); and infants exposed to maternal ZDV in utero, 1 month of postnatal ZDV, and formula-feeding (ZDV-FF). RESULTS: A total of 1719 infants were analyzed-691 HAART-BF, 503 ZDV-BF, and 525 ZDV-FF. Severe anemia was detected in 118 infants (7.4%). By 6 months, 12.5% of HAART-BF infants experienced severe anemia, compared with 5.3% of ZDV-BF (P < 0.001) and 2.5% of ZDV-FFinfants (P < 0.001). In adjusted analysis, HAART-BF infants were at greater risk of severe anemia than ZDV-BF or ZDV-FFinfants (adjusted odds ratios 2.6 and 5.8, respectively; P < 0.001). Most anemias were asymptomatic and improved with iron/multivitamin supplementation and cessation of ZDV exposure. However, 11 infants (0.6% of all infants) required transfusion for symptomatic anemia. Microcytosis and hypochromia were common among infants with severe anemia. CONCLUSIONS: Exposure to maternal HAART starting in utero was associated with severe infantanemia. Confirmation of this finding and possible strategies to mitigate hematologic toxicity warrant further study.
Authors: E S Machado; C B Hofer; T T Costa; S A Nogueira; R H Oliveira; T F Abreu; L A Evangelista; I F A Farias; R T C Mercadante; M F L Garcia; R C Neves; V M Costa; J S Lambert Journal: Sex Transm Infect Date: 2008-11-05 Impact factor: 3.519
Authors: Woong Hwan Bae; Carolyn Wester; Laura M Smeaton; Roger L Shapiro; Shahin Lockman; Kenneth Onyait; Ibou Thior; Max Essex Journal: AIDS Date: 2008-08-20 Impact factor: 4.177
Authors: Job C J Calis; Michaël Boele van Hensbroek; Rob J de Haan; Peter Moons; Bernard J Brabin; Imelda Bates Journal: AIDS Date: 2008-06-19 Impact factor: 4.177
Authors: Anirban Chatterjee; Ronald J Bosch; Roland Kupka; David J Hunter; Gernard I Msamanga; Wafaie W Fawzi Journal: Public Health Nutr Date: 2009-08-04 Impact factor: 4.022
Authors: M Fernández Ibieta; J T Ramos Amador; M I González Tomé; S Guillén Martín; J M Bellón Cano; M Navarro Gómez; M I de José; J Beceiro; E Iglesias; B Rubio; P Relaño Garrido; M J Santos; N Martínez Guardia; M A Roa; J Regidor Journal: An Pediatr (Barc) Date: 2008-12 Impact factor: 1.500
Authors: Mark Mirochnick; Timothy Thomas; Edmund Capparelli; Clement Zeh; Diane Holland; Rose Masaba; Prisca Odhiambo; Mary Glenn Fowler; Paul J Weidle; Michael C Thigpen Journal: Antimicrob Agents Chemother Date: 2008-12-29 Impact factor: 5.191
Authors: Elizabeth M Widen; Margaret E Bentley; Charles S Chasela; Dumbani Kayira; Valerie L Flax; Athena P Kourtis; Sascha R Ellington; Zebrone Kacheche; Gerald Tegha; Denise J Jamieson; Charles M van der Horst; Lindsay H Allen; Setareh Shahab-Ferdows; Linda S Adair Journal: J Acquir Immune Defic Syndr Date: 2015-07-01 Impact factor: 3.731
Authors: Elizabeth M Widen; Margaret E Bentley; Dumbani Kayira; Charles S Chasela; Eric J Daza; Zebrone K Kacheche; Gerald Tegha; Denise J Jamieson; Athena P Kourtis; Charles M van der Horst; Lindsay H Allen; Setareh Shahab-Ferdows; Linda S Adair Journal: J Nutr Date: 2013-12-31 Impact factor: 4.798
Authors: Alexander C Ewing; Caroline C King; Jeffrey B Wiener; Charles S Chasela; Michael G Hudgens; Debbie Kamwendo; Gerald Tegha; Mina C Hosseinipour; Denise J Jamieson; Charles Van der Horst; Athena P Kourtis Journal: AIDS Date: 2017-11-28 Impact factor: 4.177
Authors: Paige L Williams; Rohan Hazra; Russell B Van Dyke; Cenk Yildirim; Marilyn J Crain; George R Seage; Lucy Civitello; Angela Ellis; Laurie Butler; Kenneth Rich Journal: AIDS Date: 2016-01-02 Impact factor: 4.177
Authors: Melanie R Thomas; Diane Wara; Katherine Saxton; Mary Truskier; Margaret A Chesney; W Thomas Boyce Journal: Psychosom Med Date: 2013-06-13 Impact factor: 4.312